Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics, a clinical-stage biopharmaceutical company focused on liver and viral diseases, announced the granting of 10,700 non-qualified stock options to newly hired employees under its 2024 Inducement Plan. These grants are intended as an inducement material per Nasdaq Listing Rule 5635(c)(4), with options vesting over four years, align…